Department of Neurology, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Cancer J. 2012 Jan-Feb;18(1):59-68. doi: 10.1097/PPO.0b013e3182431a73.
Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.
胶质母细胞瘤是最具侵袭性的原发性脑肿瘤，在中枢神经系统相对免疫豁免的微环境中蓬勃生长。尽管采用了手术、放疗和化疗等治疗方法，但预后仍然较差。免疫疗法在治疗其他癌症方面的近期成功重新激发了人们对胶质母细胞瘤疫苗治疗的兴趣。本文概述了各种免疫治疗策略，回顾了最近的临床试验数据，并讨论了胶质母细胞瘤疫苗治疗的未来。
